dyspepsia
DYSPEPSIA

Dyspepsia is having any one of the following: Disturbing postprandial fullness, early satiation, epigastric pain and/or burning felt predominantly in the upper abdomen.

It is considered a symptom complex rather than a specific diagnosis.

Acid suppression is the recommended initial therapy.

Dyspepsia Signs and Symptoms

Definition

  • Refers to pain or discomfort centered in the upper abdomen
    • Discomfort refers to a subjective sensation that the patient does not interpret as pain which may be characterized by or associated with upper abdominal fullness, early satiety, bloating, belching, nausea and vomiting
    • Centered refers to pain or discomfort in or around the midline
  • Considered a symptom complex rather than a specific diagnosis

Signs and Symptoms

  • Ulcer-like
    • Chronic or recurrent epigastric pain or discomfort for at least 2-4 weeks
  • Reflux-like
    • Acid regurgitation
    • Heartburn
  • Dysmotility-like
    • Bloating in upper abdomen not accompanied by visible distension
    • Early satiety
    • Nausea and vomiting
    • Postprandial fullness
    • Upper abdominal discomfort often aggravated by food
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
05 Feb 2021

Primary immunodeficiency disease (PIDD) and allergies are two groups of conditions related to the immune system. However, they are uniquely different in terms of symptoms and treatment.

Pearl Toh, 26 Nov 2020
Inhaled corticosteroid (ICS) should be the mainstay of long-term asthma management — such is the key message of the latest Singapore ACE* Clinical Guidance (ACG) for asthma, released in October 2020.
Roshini Claire Anthony, 6 days ago

Critical or severe COVID-19 disease could raise the risk of negative perinatal outcomes in pregnant women, according to an observational study from the US.

Stephen Padilla, 22 Feb 2021
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.